Market Expansion and Strategic Agreements – Colzyx's Achieved Milestones.

In the wake of groundbreaking research at the Faculty of Medicine at Lund University, Colzyx has emerged as a trailblazer in medical technology since its establishment in 2016. Founded through the acquisition of discoveries and inventions, the company has rapidly positioned itself as a leading player in innovative wound care. Chronic wounds pose a global challenge, affecting approximately 200 million people worldwide. With an expected annual increase of 3.7%, driven by an aging population and an increased prevalence of conditions such as diabetes, Colzyx is at the forefront of addressing this growing challenge with its innovative product, WOUNDCOM, with the potential to revolutionize the treatment of chronic wounds.

In a notable stride for medical technology innovation, Colzyx announces an ambitious market expansion for WOUNDCOM. The focus is now directed towards veterinarians, and this strategic initiative has been intensified throughout the current year. This means that WOUNDCOM will now be available to veterinarians for the treatment of traumatic wounds in various species, with a particular emphasis on horses. Results from numerous case studies show overwhelmingly positive feedback and specific effectiveness in equine care. This opens up opportunities for veterinarians to reduce the use of antibiotics and anti-inflammatory drugs, benefiting both the health of the animals and their owners. The broader application scope for WOUNDCOM marks a significant advancement for Colzyx and its commitment to offering innovative solutions in medical technology. This step potentially enhances the quality of life for animals while simultaneously strengthening the company's position in the market. With this addition, Colzyx opens the door to a new era of wound care, not only for humans but also for our four-legged friends.

The company also announced that it currently holds three patent families securing their intellectual property rights, not only for WOUNDCOM but also for future innovations in wound care and potential alternatives to current antibiotics. With patent protection in Europe, the USA, and China, Colzyx has established a solid foundation for its global presence and ongoing advancements.

Another highlight for this year is the strategic production agreement with an internationally renowned producer of collagen products, enabling large-scale production of WOUNDCOM. The products have already been approved for the upcoming clinical trial, marking a significant step towards making this groundbreaking wound care product available to those in need. Colzyx continues to pave the way for a future where the effective treatment of chronic wounds improves the quality of life for millions of people worldwide.